Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|December 29, 2014
Weighing Cost Vs. Cure in Hepatitis C Treatments
Raulo Frear, PharmD, general manager of OmedaRx, discusses the high initial cost of hepatitis C drugs like Sovaldi compared with the long term cost of treating the disease.
Advertisement
Raulo Frear, PharmD, general manager of OmedaRx, discusses the high initial cost of hepatitis C drugs like Sovaldi compared with the long term cost of treating the disease.
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
4
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
5